Research Topics
| Deborah LaytonSummaryAffiliation: Drug Safety Research Unit Country: UK Publications
| Collaborators
|
Detail Information
Publications
Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in EnglandDeborah Layton
Drug Safety Research Unit, Southampton, UK
Drug Saf 32:169-79. 2009..Desloratadine is a non-sedating, long-acting histamine H(1) receptor antagonist indicated for the symptomatic relief of allergic rhinitis (AR) and chronic idiopathic urticaria in patients aged>12 years...
Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in EnglandD Layton
Department of Pharmacology, School of Medical Sciences, University of Otago, Dunedin, New Zealand
Eur J Clin Pharmacol 57:167-76. 2001..To investigate whether an association between the use of selective serotonin reuptake inhibitor (SSRI) antidepressants and abnormal bleeding is demonstrated in a large population study...- Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) dataD Layton
Drug Safety Research Unit, University of Southampton, Southampton, UK
Rheumatology (Oxford) 42:1342-53. 2003..The Drug Safety Research Unit (DSRU) monitored the post-marketing safety of these drugs in England using the non-interventional observational cohort technique of prescription-event monitoring (PEM)... - Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) dataDeborah Layton
Drug Safety Research Unit, University of Southampton, Southampton, UK
Rheumatology (Oxford) 42:1354-64. 2003..The Drug Safety Research Unit monitored the post marketing safety of these drugs in England using the non-interventional observational cohort technique of Prescription-Event Monitoring (PEM)... - Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK
Eur J Clin Pharmacol 60:489-501. 2004..A post-marketing surveillance study using the technique of Prescription Event Monitoring was undertaken to monitor the safety of celecoxib, a cyclo-oxygenase (COX)-2 inhibitor, as prescribed in primary care in England... - Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
Osteoporos Int 16:490-500. 2005..There were also a small number of reports of events associated with venous thromboembolism and visual disorders that require further investigation... - Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementiaDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
J Psychopharmacol 19:473-82. 2005..However, dementia appears to be an important risk factor. These results should be considered alongside other pharmacoepidemiological studies on this topic... - Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The NetherlandsDeborah Layton
Drug Safety Research Unit, Blundell Lane, Southampton, Hampshire, England
Drug Saf 31:143-58. 2008..The channelling paradox may exist for cyclo-oxygenase (COX)-2 selective inhibitors ('coxibs') instead of traditional nonselective NSAIDs in relation to both gastrointestinal (GI) and cardiovascular (CV) safety... - Prescriber adoption of newly approved selective COX-2 inhibitorsDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
Pharmacoepidemiol Drug Saf 17:1168-74. 2008..This study examines if COX-2 inhibitors (coxibs) were prescribed by subsets of practitioners and describes GP adoption patterns of coxibs and existing NSAIDs over time... - Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) dataD Layton
Drug Safety Research Unit, University of Southampton, Southampton, UK
Rheumatology (Oxford) 42:1332-41. 2003.... - Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring dataD Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
Rheumatology (Oxford) 42:622-31. 2003.... 
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Southampton, UK
Br J Clin Pharmacol 55:166-74. 2003..A postmarketing Prescription-Event Monitoring study was undertaken to monitor the safety of rofecoxib, a cyclo-oxygenase (COX)-2 selective inhibitor prescribed in primary care in England...- Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UKD Layton
Drug Safety Research Unit, Bursledon Hall, Southampton SO31 1AA, UK
Pharmacoepidemiol Drug Saf 11:503-13. 2002..The aim of this initial pilot work, using an observational cohort design, was to determine the feasibility of conducting a pharmacovigilance study of a non-prescription medicine, based in community pharmacies... - A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational dataRachna Kasliwal
Drug Safety Research Unit, Southampton, UK
Drug Saf 28:803-16. 2005.... - Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in EnglandDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Southampton, UK
Drug Saf 29:687-96. 2006..008% for all four cohorts combined). Prescribers and patients should be aware of the severe and life-threatening risk of EM potentially associated with NSAIDs, including COX-2 selective inhibitors... - Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiologyDavid W J Clark
New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, School of Medicine and Department of Pharmacology and Toxicology, School of Medical Sciences, University of Otago, Dunedin, New Zealand
Drug Saf 27:427-56. 2004..This is particularly important in the elderly, in patients with cardiovascular/renal disease and in patients with other risk factors that might predispose them to adverse events... - Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in EnglandDeborah Layton
Drug Safety Research Unit, Southampton, Hants, UK
Drug Saf 29:897-909. 2006..However, essential components of the comparative benefit-risk evaluation of these two products include assessment of efficacy and patient preference (neither of which forms part of this study)... - Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring dataD Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
J Clin Pharm Ther 29:171-81. 2004..Hypotheses arising from signal generation require evaluation and cannot be taken as a conclusive evidence for clinical differences in the safety profiles of drugs... - Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in EnglandVicki Osborne
Drug Safety Research Unit, Bursledon Hall, Southampton, UK
Drug Saf 33:579-91. 2010..Strontium ranelate is indicated for the treatment of postmenopausal osteoporosis. An association between strontium ranelate and venous thromboembolism (VTE) was identified in an analysis of phase III clinical trials... - Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk managementVicki Osborne
Drug Safety Research Unit, Bursledon Hall, Southampton, UK
Drug Saf 33:213-21. 2010.... - Safety profile of oxcarbazepine: results from a prescription-event monitoring studyYvonne Buggy
Drug Safety Research Unit, Southampton, United Kingdom
Epilepsia 51:818-29. 2010..To monitor safety of oxcarbazepine, prescribed in primary care in England, using prescription-event monitoring (PEM)... - Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk managementDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
Drug Saf 34:e1-9. 2011..M-PEM studies therefore have an important contribution to make to pharmacovigilance and the risk management of medicines by providing valuable information on the use of new medications under real-life situations... - Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safetyCheryl Key
Drug Safety Research Unit, Burseldon Hall, Southampton SO31 1AA, UK
Pharmacoepidemiol Drug Saf 11:143-8. 2002..While research remains a non-core activity and receives no payment, participation is likely to fall. Researchers need to find means of benefiting the general practitioner if participation is to continue... - Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring databaseD W Clark
Drug Safety Research Unit, Bursledon Hall, Southampton, UK
Drug Saf 24:1143-54. 2001..This requires further investigation by other types of epidemiological study... - Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring dataDeborah Layton
Drug Safety Research Unit, Southampton, UK
Drug Saf 34:1177-89. 2011..Levocetirizine was launched onto the UK market in September 2001. It is indicated for symptomatic treatment of allergic rhinitis (AR), including persistent AR and chronic idiopathic urticaria... - Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the futureDeborah Layton
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton SO31 1AA, UK
Pharmacoepidemiol Drug Saf 12:31-40. 2003..Such proactive surveillance could avoid unnecessary delays for other drugs where QT prolongation and serious cardiac arrhythmias may be an issue... - Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteriaSaad A W Shakir
Drug Safety Research Unit, Bursledon Hall, Southampton, United Kingdom
Drug Saf 25:467-71. 2002..Further work is required to develop strategies to handle these limitations... - Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of YasminHilary M Pearce
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, UK
Br J Clin Pharmacol 60:98-102. 2005..3, 23.4). CONCLUSIONS: Yasmin is associated with venous thromboembolism. An incidence rate has been calculated, but this may be subject to bias and should be interpreted with caution... - Prescription-event monitoring and reporting of adverse drug reactionsE Heeley
Drug Safety Research Unit, Bursledon Hall, SO31 1AA, Southampton, UK
Lancet 358:1872-3. 2001..Our results should not be extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous reports... - Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoringD Layton
Drug Safety Research Unit, Southampton, England
Drug Saf 24:703-13. 2001..CONCLUSIONS: Tolterodine is well tolerated in general practice at the recommended daily dose. Hallucinations, tachycardia and palpitations are infrequently associated with the drug... - Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring studyB Twaites
Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire SO31 1AA, UK
Acta Diabetol 44:233-9. 2007..Two pregnancies (< 0.1%) and 73 deaths (1.6%) were reported. Nateglinide appeared to be generally well tolerated when used in combination with metformin for the treatment of Type 2 diabetes... - Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomesIsla S Mackenzie
Medicines Monitoring Unit, Division of Medical Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
Br J Clin Pharmacol 73:801-11. 2012.... - New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UKElizabeth Lynn
Drug Safety Research Unit, Bursledon Hall, Southampton, UK
Drug Saf 34:89-91. 2011..Flexibility is ensured by the availability of a wide choice of units, the use of online facilities for learning and assessment, and the possibility that previous relevant training or experience may be counted towards the awards...